Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Leadership Restructuring Sales & Earnings

Philips Commits To ESG And AI While Servicing Respironics Recall Priority

Company Agrees Terms Of US Consent Decree And CEO Remains Bullish On Outlook

  • Analysis

Executive Summary

Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.

Table

View full table

Related Content

Medtech Insight

Topics

Related Companies

Tags:
Leadership Restructuring Sales & Earnings
Latest Headlines

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

It’s Official: FDA Drops Final Rule On LDTs

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

See All
UsernamePublicRestriction

Register

MT154423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By